Compare Docusign Inc (DOCU) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Illumina, Inc. — how do they compare? Docusign Inc trades at $49.5 (market cap $9.43B), while Illumina, Inc. trades at $191.2 (market cap $28.93B). The key difference: Illumina, Inc. is far larger — about 3.1× Docusign Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | ILMN | |
|---|---|---|
Market Cap | $9.43B | $28.93B |
Sector | Technology | Health |
52-Week High | $85.01 | $194.33 |
52-Week Low | $41.75 | $91.00 |
Enterprise Value | $8.80B | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $49.87, up 1.4% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growth to $2.98B in 2025 and net income of $1.07B, supported by consistent earnings beats. Recent partnerships with Perplexity and Slack highlight innovation in agreement management, while analyst sentiment remains mixed with a $55.40 consensus target.
Outlook is cautiously optimistic given solid profitability and strategic initiatives, but risks include pricing pressure and sector volatility. The stock presents a growth opportunity if execution continues, though investor patience is required amid competitive and macroeconomic headwinds.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
